Curebase has supported InBios International in securing US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its SCoV-2 Detect IgG Rapid Test.

The company collaborated with InBios to test its Covid-19 rapid test, which is an in-vitro lateral flow chromatographic immunoassay.

The device is designed to detect IgG antibodies of SARS-CoV-2 in human serum, plasma, venous whole blood and fingerstick whole blood.

It is developed to identify individuals with an adaptive immune response to SARS-CoV-2, which indicates recent or prior infection.

Curebase noted that the IgG Rapid Test should not be used to identify or exclude acute SARS-CoV-2 infection.

A clinical study was conducted using Curebase solution on individuals who were 15 days or more post symptom onset.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In this trial, the SCoV-2 Detect IgG Rapid Test showed 96.9% (PPA) of those who were positive and 100% of those who were negative (NPA) for SARS-CoV-2 IgG antibodies.

The new Covid-19 test also includes all reagents and controls which are needed to perform 50 test specimens with results in about 20 minutes.

Curebase founder and CEO Tom Lemberg said: “By locally activating points of care in the community to collect clinical data, such as drive-through testing sites, we can more conveniently and quickly obtain data for the FDA’s requirements.”

The company noted the InBios’s SCoV-2 Detect IgG Rapid Test has only been authorised for emergency use by the FDA for use by authorised laboratories and has not been FDA cleared or approved.

It has been approved only to detect the IgG antibodies presence of SARS-CoV-2, not for the detection of any other viruses or pathogens.

The product’s authorisation is only for the duration of the declaration that circumstances exist which justifies the EUA of vitro diagnostics to detect and/or diagnose Covid-19.